Site Search
Professionals 99 results
Capabilities 42 results
Industry
Winston has been a major player in the life sciences industry for decades. We represent market-leading clients across this broad sector, including companies involved in pharmaceuticals, biologics, biosimilars, biotechnology, and medical devices. Our attorneys are seasoned practitioners—many of whom have technical degrees in areas key to the life sciences sector, including biology, chemistry, pharmacy, and biomedical engineering—and bring a unique understanding of the industry and perspective to our representations.
Practice Area
As society and business become even more digitalized, technology and intellectual property (IP) have become key focal points for businesses. Our Technology Antitrust Group combines the cross-practice and cross-office experience of our lawyers to assist clients in successfully navigating the dynamic convergence of technology, antitrust, and IP law. We understand the challenges presented by the ever-changing digital landscape and are committed to providing our clients with tailored solutions to address their specific needs.
Practice Area
Trade Secrets, Non Competes & Restrictive Covenants
Theft of trade secrets and other confidential information occurs all too frequently in today’s global, highly mobile, and competitive marketplace. In the course of advising clients, we have developed comprehensive, yet scalable, strategies for both mitigating against and responding to issues along the trade secrets protection spectrum, including helping position clients proactively before trade secrets theft occurs.
Experience 102 results
Experience
|May 27, 2025
Experience
|April 11, 2025
Cuprina Holdings (Cayman) Limited Announces Closing of Initial Public Offering
Experience
|April 10, 2025
Titan Acquisition Corp Announces Closing of $276,000,000 Initial Public Offering
Insights & News 696 results
Seminar/CLE
|June 23 - June 24, 2025
2025 Chicago SBIC Fund Reception & Conference
Winston & Strawn LLP and RSM US LLP are co-hosting the Chicago SBIC (Small Business Investment Company) Fund Conference on June 23-24, 205.
Client Alert
|June 12, 2025
|3 Min Read
Oregon Enacts SB 951, Restricting PE-Backed MSOs in Physician Practice Transactions
On June 9, 2025, Oregon enacted Senate Bill 951 (SB 951), a sweeping new law significantly limiting how management services organizations (MSOs)—including those backed by private-equity firms—may engage with physician practices. The legislation targets traditional “friendly provider” models by restricting ownership and operational control of professional medical entities and voiding restrictive covenants. Investors must now reassess Oregon-based physician practice investments to ensure compliance by 2026 (for new MSOs) and 2029 (for existing ones). It’s noteworthy that this law will coexist with Oregon’s complicated health care transactions notice law, a law that requires a thorough review of certain health care transactions.
In the Media
|June 2, 2025
|1 Min Read
Aparna Sehgal Participates in Real Estate Capital Europe Alternative Lenders Roundtable Discussion
Winston & Strawn partner Aparna Sehgal was featured in Real Estate Capital Europe’s Alternative Lenders roundtable. The participants discussed topics including the effects of widening spreads on back leverage arrangements, predictions for U.K. and European interest rates, how the widening of U.S. credit spreads will impact pricing and loan terms available from alternative lenders that are borrowing from U.S. banks, and the scope of growth for the European alternative real estate debt market.
Other Results 33 results
Site Content
What Is the Price Range in an IPO?
The price range is a proposed price per share range for the IPO within which investors can bid for shares and which is often printed on the cover page of a preliminary prospectus. The price range has a minimum price, known as the floor price, and a maximum price, known as the cap price.
Site Content
Congress enacted the Biologics Price Competition and Innovation Act (BPCIA) to provide an abbreviated pathway for biosimilars to gain FDA approval through submission of an abbreviated Biologics License Application (aBLA).
Site Content
Dilution refers to the reduction in an existing shareholder’s ownership percentage of a company when the company issues additional shares. Dilution in an IPO results from a disparity between the public offering price in an IPO and the effective cash cost to persons who acquired shares prior to the IPO. Dilution is disclosed in the registration statement in a dilution table.